Immunoreactivity of p53,mdm2,and p21WAFL in Dedifferentiated Liposarcoma: Special Emphasis on the Distinct Immunophenotype of the Well-differentiated Component

Abstract

Alteration of the p53/mdm2 pathway has been reported in the well-differentiated iiposarcoma (WDLS)/dedifferentiated liposarcoma (DDLS) group. We investigated the immunoreactivity of p53, mdm2, and p21^WAF1, along with the MIB-I-labeling index (MIB-1-LI) in 21 WDLS and 21 DDLS cases, to clarify the association of these markers with the morphologic changes and the biological factors responsible for the aggressiveness of DDLS. Within DDLS, p53 and p21^WAF1 expression and mdm2 overexpression were significantly more prevalent in the dedifferentiated (DD) components than in the well-differentiated (WD) components. The mdm2 overexpression and p2l^WAFl expression was significantly associated with sclerosing liposarcomas in both WDLS and the WD components of DDLS. There was no significant difference in the immunoreactivity of p53, mdm2, or p21^WAF1 or MIB-1-LI between WDLS and the WD components of DDLS. An association was found between p53 expression and mdm2 overexpression in the WD group (comprising WDLS and WD components of DDLS) and in the DD group, significantly so in the WD group. Notably, this correlation was found in the subtype of sclerosing liposarcoma but not in that of lipoma-like liposarcoma. Within DDLS, the clinical outcome of the nonaccessible soft tissue (nonAST: comprising retroperitoneum and mediastinum) group was significantly worse than that of the accessible soft tissue (AST: comprising extremities, buttocks, axilla, and scrotum) group; however, the immunophenotypes of p53, mdm2, and p21^WAF1 and the MIB-1-LI showed no correlation with survival in the AST group alone, in the non-AST group alone, or in the 2 together. This study suggests that the immunoreactivity of p53, mdm2, and p21^WAFl is associated with the morphologic changes, but not with the biological factors responsible for the aggressiveness of DDLS.

Keywords

dedifferentiated liposarcoma immunohistochemistry mdm2 p21WAF1/CIP1/SDI1 p53 well-differentiated liposarcoma

Get full access to this article

View all access options for this article.

References

1. Evans HL . Liposarcoma : A study of 5 5 cases with a reassessment of its classification. Am J Surg Pathol 3:507-523, 1979

2. Enzinger FM , Weiss SW . Liposarcoma . In Enzinger FM , Weiss SW (eds): Soft tissue tumors, 3rd ed. Mosby, St Louis, pp. 431-466, 1995

3. Evans HL , Khurana KK , Kemp BL , Ayala AG . Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol 18:1150-1157, 1994

4. Henricks WH , Chu YC , Goldblum JR , Weiss SW . Dedifferentiated liposarcoma: A clinicopathologic analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 21:271-281, 1997

5. Hollstein M , Sidransky D , Vogelstein B , Harris CC . p53 mutations in human cancers. Science 253:49-53, 1991

6. Greenblatt MS , Bennett WP , Hollstein M , Harris CC . Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994

7. Levine AJ , Momand J , Finlay CA . The p53 tumour suppressor gene. Nature 351:453-456, 1991

8. Reich NC , Oren M , Levine AJ . Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 3:2143-2150, 1983

9. Ciechanover A , DiGiuseppe JA , Bercovich B , Orian A , Richter JD , Schwartz AL , Brodeur GM . Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 88:139-143, 1991

10.

10. Latres E , Drobnjak M , Pollack D , Oliva MR , Ramos M , Karpeh M , Woodruff JM , Cordon-Cardo C. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 145:345-355, 1994

11.

11. Kohler MF , Berchuck A , Davidoff AM , Humphrey PA , Dodge RK , Iglehart JD , Soper JT , Clarke-Pearson DL , Bast RC Jr , Marks JR . Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622-1627, 1992

12.

12. Cordon-Cardo C , Latres E , Drobnjak M , Oliva MR , Pollack D , Woodruff JM , Marechal V , Chen J , Brennan MF , Levine AJ . Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799, 1994

13.

13. Leach FS , Tokino T , Meltzer P , Burrell M , Oliner JD , Smith S , Hill DE , Sidransky D , Kinzler KW , Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53 (Suppl): 2231-2234, 1993

14.

14. Marchetti A , Buttitta F , Pellegrini S , Merlo G , Chella A , Angeletti CA , Bevilacqua G. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4:93-97, 1995

15.

15. Keleti J , Quezado MM , Abaza MM , Raffeld M , Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wildtype p53 protein. Am J Pathol 149:143-151, 1996

16.

16. Dei Tos AP , Doglioni C , Piccinin S , Maestro R , Mentzel T , Barbareschi M , Boiocchi M , Fletcher CD . Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol 181:8-13, 1997

17.

17. Nakayama T , Toguchida J , Wadayama B , Kanoe H , Kotoura Y , Sasaki MS . MDM2 gene amplification in bone and soft-tissue tumors: Association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 64:342-346, 1995

18.

18. Elgar F , Goldblum JR . Well-differentiated liposarcoma of the retroperitoneum: A clinicopathologic analysis of 20 cases, with particular attention to the extent of low-grade dedifferentiation. Mod Pathol 10:113-120, 1997

19.

19. Mentzel T , Fletcher CDM . Lipomatous tumors of the soft tissues: An update. Virchows Arch 427:353-363, 1995

20.

20. Fletcher CD , Akerman M , Dal Cin P , de Wever I , Mandahl N , Mertens F , Mitelman F , Rosai J , Rydholm A , Sciot R , Tallini G , van den Berghe H , van de Ven W , Vanni R , Willen H. Correlation between clinicopathological features and karyotype in lipomatous tumors. Am J Pathol 148:623-630, 1996

21.

21. Rosai J , Akerman M , Dal Cin P , DeWever I , Fletcher CD , Mandahl N , Mertens F , Mitelman F , Rydholm A , Sciot R , Tallini G , Van den Berghe H , Van de Ven W , Vanni R , Willen H. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol 20:1182-1189, 1996

22.

22. Dal Cin P , Kools P , Sciot R , De Wever I , Van Damme B , Van de Ven W , Van den Berghe H. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet 68:85-90, 1993

23.

23. Pedeutour F , Forus A , Coindre JM , Berner JM , Nicolo G , Michiels JF , Terrier P , Ranchere-Vince D , Collin F , Myklebost O , Turc-Carel C. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 24:30-41, 1999

24.

24. Berner J-M , Forus A , Elkahloun A , Meltzer PS , Fodstad O , Myklebost O . Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer 17:254-259, 1996

25.

25. Dei Tos AP , Doglioni C , Piccinin S , Sciot R , Furlanetto A , Boiocchi M , Dal Cin P , Maestro R , Fletcher CD , Tallini G. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 190:531-536, 2000

26.

26. Pilotti S , Della Torre G , Lavarino C , Di Palma S , Sozzi G , Minoletti F , Rao S , Pasquini G , Azzarelli A , Rilke F , Pierotti MA . Distinct mdm2/p53 expression patterns in liposarcoma subgroups: Implications for different pathogenetic mechanisms. J Pathol 181:14-24, 1997

27.

27. Buto S , Pierotti MA , Tamborini E , Della Torre G , Lavarino C , Rilke F , Pilotti S. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection. Diagn Mol Pathol 8:125-130, 1999

28.

28. Hasegawa T , Seki K , Hasegawa F , Matsuno Y , Shimodo T , Hirose T , Sano T , Hirohashi S. Dedifferentiated liposarcoma of retroperitoneum and mesentery: Varied growth patterns and histological grades-a clinicopathologic study of 32 cases. Hum Pathol 31:717-727, 2000

29.

29. Baretton GB , Klenk U , Diebold J , Schmeller N , Lohrs U. Proliferationand apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAFl/CIPI expression. Br J Cancer 80:546-555, 1999

30.

30. Korkolopoulou P , Kouzelis K , Christodoulou P , Papanikolaou A , Thomas-Tsagli E. Expression of retinoblastoma gene product and p21 (WAFI/Cip 1) protein in gliomas: Correlations with proliferation markers, p53 expression and survival. Acta Neuropathol 95:617-624, 1998

31.

31. Erber R , Klein W , Andl T , Enders C , Born Al , Conradt C , Bartek J , Bosch FX . Aberrant p21 (CIPI/WAFI) protein accumulation in head-and-neck cancer. Int J Cancer 74:383-389, 1997